Rx (Prescription Medicine)
USD $ 120.00
Hersima 440mg Injection 是一种用于治疗特定类型癌症的靶向疗法。其活性成分 Trastuzumab 是一种单克隆抗体，可特异性结合 HER2 蛋白。许多癌细胞（尤其是乳腺癌和胃癌）过度表达 HER2 蛋白，促进其生长与增殖。Hersima 通过与癌细胞表面的 HER2 受体结合，阻断传导细胞生长与分裂的信号。同时，它还能将癌细胞标记为被机体免疫系统破坏。Hersima 通常由医护专业人员通过静脉注射给药。剂量及治疗时长取决于癌症的具体类型、分期以及患者个体的反应。常见不良反应可能包括发热、寒战、恶心、呕吐、腹泻和疲劳。较少见的情况可能涉及心脏问题或严重过敏反应。储存说明应遵循生产厂家的指南，通常需要冷藏并避光保存。请务必咨询您的医疗提供者，获取关于 Hersima 的个性化医疗建议。
| Medicine Form | |
|---|---|
| Rx Status | |
| Medicine Type | |
| Molecule | |
| Pack Quantity | |
| Strength |
其他品牌的 Trastuzumab 440 mg — 同一活性成分且强度相同，但来自不同制造商。
医学审核
Renu Meena, B.Pharm
Medical Content Writer
Renu Meena is an experienced Medical Content Writer with a strong foundation in pharmacy practice. She holds a Bachelor of Pharmacy (B.Pharm) degree from Rajasthan University of Health Sciences (RUHS), Jaipur, and is registered with the Rajasthan State Pharmacy Council (Reg. No. 55661). With 4+ years of experience across clinical pharmacy and medical content development, she creates evidence-based content for medicines, diseases, and patient education. Her work is shaped by a strong understanding of pharmacovigilance and regulatory standards, including ICH guidelines, GVP modules, ICD-10/11, and safety reporting requirements. Renu focuses on making complex medical information simple, accurate, and useful for readers while maintaining high quality and compliance.
